Diagnosis, Screening, and Early Detection of Merkel Cell Carcinoma

• Merkel cell carcinoma early warning signs include a rapidly growing, firm, painless nodule — often red, purple, or skin-colored — usually appearing on sun-exposed skin such as the head, neck, or arms.
• A definitive diagnosis requires a skin biopsy, followed by pathological examination and immunohistochemistry; a positive cytokeratin 20 (CK20) stain is a key marker used to confirm MCC.
• Imaging tests help check whether MCC has spread — commonly CT, with PET or MRI reserved for select cases — though there’s no single standard protocol, so testing is tailored to each patient.
• People at higher risk — including those over 50, or with a weakened immune system — are often offered more frequent skin exams by a dermatologist, in addition to their own regular skin self-checks.
• Because MCC tends to grow and spread quickly, prompt evaluation of any new or changing skin lesion matters, even though population-wide skin cancer screening has not been proven to lower death rates.

Recognizing Early Signs of Merkel Cell Carcinoma

Identifying Merkel cell carcinoma early warning signs is critical for prompt medical intervention. MCC is a distinct, neuroendocrine skin cancer — different from more common skin cancers like basal cell, squamous cell, or melanoma — and unlike many of those, it often presents without pain or tenderness, which can sometimes delay diagnosis. Understanding the typical presentation can help people seek timely medical advice.

Visual Cues and Skin Changes

The characteristic signs and symptoms of Merkel cell carcinoma usually manifest as a single, rapidly growing lesion on the skin. These lesions are typically:

• Firm and Dome-Shaped: They often feel hard to the touch and protrude from the skin.
• Shiny Appearance: The surface of the nodule may appear smooth and glistening.
• Red or Violet Color: While they can be skin-colored, many MCC lesions have a reddish, purplish, or violet hue.
• Painless: A key feature that distinguishes MCC from many other skin conditions is its lack of pain or tenderness, which can be misleading.
• Location: These tumors tend to develop where skin gets the most sun exposure — the head, neck, arms, or legs — though they can occur anywhere on the body.

The acronym AEIOU can help remember these features: Asymptomatic (painless), Expanding rapidly, Immune suppression (a risk factor), Older than 50, and UV-exposed site. According to the National Cancer Institute, MCC is rare: about 0.7 out of every 100,000 people in the U.S. were diagnosed annually as of 2013, a number that has climbed over the past few decades, likely alongside better diagnostic tools, wider clinical awareness, and an older population overall. It occurs mostly in people over 50, with an average age at diagnosis in the mid-60s.

When to Seek Medical Attention

Given the aggressive nature of MCC, it is important to seek medical attention promptly for any new, rapidly growing, or changing skin lesion, especially one that fits the description above. Do not wait for pain or discomfort, since these symptoms are often absent. A dermatologist or primary care physician should evaluate any suspicious skin change to determine the underlying cause and next steps.

Initial Steps: How to Diagnose Merkel Cell Carcinoma

Diagnosing Merkel cell carcinoma begins with a thorough clinical assessment, followed by tissue sampling. Because the cancer can grow and spread quickly, timely and accurate diagnosis matters.

Clinical Examination and History

When a patient presents with a suspicious skin lesion, the first step is a full-body skin exam by a healthcare professional, including a visual inspection of the lesion, palpation to assess its texture and depth, and a check of nearby lymph nodes for swelling. The doctor will also take a detailed medical history, asking about the lesion’s onset and growth rate, other symptoms, and the patient’s overall health, including any history of immune suppression or previous skin cancers.

Biopsy Procedures

A definitive diagnosis cannot be made without a biopsy — the removal of a small tissue sample for examination by a pathologist. Several biopsy techniques may be used:

• Punch Biopsy: A circular tool is used to remove a core of tissue, including deeper layers of the skin.
• Incisional Biopsy: A portion of the lesion is surgically removed.
• Excisional Biopsy: The entire lesion is surgically removed, often with a margin of healthy tissue; this is often preferred if the lesion is small and easily accessible.

The sample is then examined under a microscope, with immunohistochemistry used to identify markers characteristic of MCC and to help rule out other cancers that can look similar.

Advanced Merkel Cell Carcinoma Diagnosis Methods

Beyond the initial biopsy, further evaluation helps determine the extent of the disease. This process, called staging, guides treatment decisions.

Imaging Techniques for Staging

Once MCC is confirmed by biopsy, tests may be done to check whether the cancer has spread to nearby lymph nodes or distant organs. There is no single standardized imaging work-up for MCC, so the specific tests used are tailored to each patient’s case. They can include:

• Computed Tomography (CT) Scans: May be used to check the chest, abdomen, and other areas for spread to lymph nodes or organs, and to help distinguish MCC from a lung small-cell carcinoma that can look similar.
• Positron Emission Tomography (PET) Scans: Involves injecting a radioactive tracer that highlights areas where cells are especially active, which can include cancer; PET, sometimes combined with CT, has been reported in select MCC cases but is not a routine part of every work-up.
• Magnetic Resonance Imaging (MRI): May be considered for select presentations, such as head-and-neck tumors, though its role in MCC has not been formally studied.
• Sentinel Lymph Node Biopsy (SLNB): Removes the first lymph node(s) that a tumor is likely to drain into, to check for cancer cells. It is an important staging tool for MCC, since lymph node involvement is common and affects the stage assigned to the cancer.

Pathological Confirmation

A definitive diagnosis relies on detailed pathological examination of the biopsy sample. Pathologists use immunohistochemistry to help confirm MCC and distinguish it from other cancers that can look similar under the microscope. Key elements include:

• Cytokeratin 20 (CK20): MCC cells are characteristically positive for CK20 on immunohistochemistry, one of the defining features pathologists look for.
• A Broader Marker Panel: A panel of immunohistochemical stains, anchored by CK20, helps distinguish MCC from other cancers with a similar appearance, including small cell lung carcinoma, lymphoma, and other neuroendocrine tumors — an important distinction, since MCC is treated differently from these other cancers.
• Merkel Cell Polyomavirus (MCPyV): This virus is linked to most MCC tumors in the U.S. — NCI cites a range of 70% to 80% — though not every case tests positive for it, and its presence can support, but is not required for, the diagnosis.

This analysis is essential not only for confirming the diagnosis but also for ruling out other cancers with a similar microscopic appearance, so the patient receives the correct treatment.

Screening and Early Detection Strategies

Because MCC can grow and spread quickly, closer surveillance and prompt evaluation of new lesions are especially important for people at higher risk. The goal is to find lesions before they have a chance to spread.

High-Risk Groups and Surveillance

Certain factors are associated with a higher risk of developing MCC:

• Age: MCC risk rises with age — it is uncommon before 50, and the average age at diagnosis is in the mid-60s.
• Weakened Immune System: Risk climbs substantially when immune defenses are lowered — for example, by anti-rejection drugs after an organ transplant, by HIV infection, or by chronic lymphocytic leukemia.
• History of Other Cancers: A prior history of other cancers can also increase risk.
• UV Exposure: Substantial exposure to natural or artificial sunlight (including tanning beds) is a well-documented risk factor.
• Sex and Race: MCC occurs somewhat more often in men than women, and has been reported more frequently among White populations than Black populations in the U.S., though it remains rare across all groups.

For people in these higher-risk groups, clinicians often recommend closer surveillance — for example, more frequent full-body skin exams by a dermatologist — to help catch new or changing lesions early. MCC incidence is also higher across immunosuppressed populations overall, which is part of why clinicians pay closer attention to skin changes in these patients.

The Role of Regular Skin Checks

Beyond professional surveillance, regular skin self-checks can help you notice new or changing lesions between visits. A monthly full-body check, using a mirror for hard-to-see areas, is a reasonable habit, with extra attention to sun-exposed skin. Any suspicious lesion — especially one that is rapidly growing, firm, shiny, or red/violet and painless — should be evaluated by a healthcare provider promptly. Large studies have not yet shown that routine skin self- or clinical exams reduce skin cancer deaths at a population level, but for a fast-growing cancer like MCC, prompt evaluation of a new or changing lesion remains the most useful step an individual can take.

Frequently Asked Questions

What are the most common early signs of Merkel cell carcinoma?

The most common early warning signs include a rapidly growing, painless, firm, and shiny nodule on the skin. These lesions often appear red, violet, or skin-colored and typically develop on sun-exposed areas like the head, neck, or limbs. Unlike many other skin conditions, MCC lesions are usually asymptomatic — they do not cause pain, itching, or tenderness — which can sometimes delay recognition. Any new or changing skin lesion with these characteristics warrants prompt medical evaluation.

How is Merkel cell carcinoma definitively diagnosed?

A definitive diagnosis requires a biopsy of the suspicious lesion. A pathologist examines the tissue sample under a microscope and typically uses immunohistochemistry — a positive cytokeratin 20 (CK20) stain is a defining feature — to confirm MCC and rule out other skin cancers or neuroendocrine tumors, such as small cell lung carcinoma, that can look similar.

Who is at highest risk for Merkel cell carcinoma and what are the screening recommendations?

People at highest risk include those over 50 (the average age at diagnosis is in the mid-60s), those whose immune defenses are lowered (for example, organ transplant recipients, people with HIV, or chronic lymphocytic leukemia), and those with significant UV exposure or a history of other cancers. For these groups, clinicians often recommend more frequent skin exams by a dermatologist, along with monthly self-checks to catch new or changing lesions. Prompt evaluation of any suspicious finding matters most for early detection.

Sources

• National Cancer Institute – Merkel Cell Carcinoma Treatment (PDQ®)–Patient Version
• National Cancer Institute – Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version
• National Cancer Institute – Skin Cancer Screening (PDQ®)–Patient Version